Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis. by Wijnant, Gert-Jan et al.
LSHTM Research Online
Wĳnant, Gert-Jan; Croft, Simon L; de la Flor, Raul; Alavĳeh, Mo; Yardley, Vanessa; Braillard,
Stéphanie; Mowbray, Charles; Van Bocxlaer, Katrien; (2019) Pharmacokinetics and pharmacodynam-
ics of the nitroimidazole DNDI-0690 in mouse models of cutaneous leishmaniasis. Antimicrobial agents
and chemotherapy. ISSN 0066-4804 DOI: https://doi.org/10.1128/aac.00829-19
Downloaded from: http://researchonline.lshtm.ac.uk/4653615/
DOI: https://doi.org/10.1128/aac.00829-19
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
https://researchonline.lshtm.ac.uk
1 
Title/Running Title: Pharmacokinetics and pharmacodynamics of the nitroimidazole DNDI-1 
0690 in mouse models of cutaneous leishmaniasis  2 
 3 
Byline: Gert-Jan Wijnant1, Simon L. Croft1, Raul de la Flor2, Mo Alavijeh2, Vanessa Yardley1, 4 
Stéphanie Braillard3, Charles Mowbray3, Katrien Van Bocxlaer1, 4* 5 
Affiliations: 6 
1 London School of Hygiene & Tropical Medicine, Faculty of Infectious and Tropical Diseases, 7 
Keppel Street, London WC1E 7HT, UK 8 
2 Pharmidex Pharmaceutical Services Ltd, 14 Hanover Street, London W1S 1YH, UK 9 
3 Drugs for Neglected Disease initiative (DNDi), Chemin Louis Dunant 15, 1202 Geneva, 10 
Switzerland 11 
4 York Biomedical Research Institute, Department of Biology, University of York, York, YO10 12 
5DD, UK 13 
 14 
*Corresponding author: Katrien Van Bocxlaer, York Biomedical Research Institute, Department 15 
of Biology, University of York, York, YO10 5DD, United Kingdom, 16 
katrien.vanbocxlaer@york.ac.uk, phone: 01904328855 17 
 18 
Abstract: 19 
The nitroimidazole DNDI-0690 is a clinical drug candidate for visceral leishmaniasis (VL) that 20 
also shows potent in vitro and in vivo activity against cutaneous leishmaniasis (CL). To support 21 
further development of this compound into a patient-friendly oral or topical formulation for CL, 22 
we investigated the free drug exposure at the dermal site of infection and subsequent 23 
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2 
elimination of the causative Leishmania pathogen. This study evaluates the pharmacokinetics 24 
(PK) and pharmacodynamics (PD) of DNDI-0690 in mouse models of CL. Skin microdialysis and 25 
Franz diffusion cell permeation studies revealed that DNDI-0690 permeated poorly (< 1 %) into 26 
the skin lesion upon topical drug application (0.063 % W/V, 30 µl). In contrast, a single oral dose 27 
of 50 mg/kg resulted in the rapid and near-complete distribution of protein-unbound DNDI-28 
0690 from the plasma into the infected dermis (fAUC0-6h, tissue / fAUC0-6h blood > 80 %). Based on in 29 
vivo bioluminescence imaging, two doses of 50 mg/kg DNDI-0690 were sufficient to reduce L. 30 
mexicana parasite load by 100-fold, while 6 such doses were needed to achieve similar killing of 31 
L. major; this was confirmed by quantitative PCR. The combination of rapid accumulation and 32 
potent activity in the Leishmania-infected dermis indicates the potential of DNDI-0690 as a 33 
novel oral treatment for CL.  34 
 35 
Keywords: cutaneous leishmaniasis, drug development, microdialysis, skin pharmacokinetics, 36 
rate of kill 37 
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3 
Introduction  42 
 43 
Leishmaniasis is a poverty-associated infectious disease that has two main forms: visceral 44 
leishmaniasis (VL) and cutaneous leishmaniasis (CL). While VL is almost invariably fatal if left 45 
untreated, CL is not life-threatening but causes disfiguring skin lesions associated with severe 46 
social stigma and psychological morbidity (1). The different types of CL have a wide geographic 47 
distribution and vary in causative Leishmania parasite species, which are transmitted to humans 48 
by infected female sand-flies. In the Middle-East, “Old World” L. major and L. tropica CL 49 
commonly present as local papules, nodules or ulcers that are mostly self-limiting, but often 50 
leave lifelong scars on the exposed skin areas. After healing, L. tropica CL can relapse into a 51 
persisting, chronic form called leishmaniasis recidivans. In Central and South America, “New 52 
World” parasite species of the Leishmania subgenus, such as L. mexicana, generally cause mild 53 
forms of CL, while more complicated forms involving the mucous membranes of nose, throat 54 
and mouth are observed in patients infected with the Viannia subgenus, for example L. 55 
braziliensis (2, 3). An additional cutaneous manifestation is post-kala azar dermal leishmaniasis 56 
(PKDL), a cutaneous sequela that can occur following the resolution of VL caused by L. 57 
donovani, characterised by widespread macular or papular lesions (3, 4). Worldwide, around 58 
0.7 to 1.2 million new cases of CL occur every year and around 1 billion people are at risk, 59 
mostly those living in resource-poor environments (5). At present, treatment of CL is based on 60 
four drugs: pentavalent antimonials, miltefosine, amphotericin B and paromomycin. All of these 61 
have well-documented limitations of effectiveness, toxicity, cost or route of administration (6, 62 
7). The Drugs for Neglected Diseases initiative (DNDi), a non-profit drug development 63 
partnership, has a strategy to deliver much-needed new drugs for CL. DNDi defines the optimal 64 
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4 
Target Product Profile (TPP) of a new chemical entity for CL as follows: (i) activity against all 65 
species of Leishmania causing CL (> 15), (ii) minimum 95% clinical efficacy and minimal scarring 66 
after accelerated healing of the skin lesions, (iii) oral or topical formulation for a maximum of 7 67 
or 14 days, respectively (iv) well-tolerated and safe in pregnancy and (v) cost under $5 per 68 
course (8). Whilst topical formulations hold potential for the treatment of simple, self-healing 69 
lesions, oral drugs could be used for cases with a higher risk of parasite dissemination; both 70 
routes of administration avoid the need for painful drug injections that are currently common 71 
(9). 72 
Nitroimidazoles are a medically important class of antimicrobial agents with a broad spectrum 73 
of activity, including against protozoan parasites such as Trichomonas vaginalis, Trypanosoma 74 
cruzi and Giardia (10). The prototype molecule for this class, metronidazole, was discovered in 75 
the 1950s, and in recent years there has been a renewed interest in the therapeutic potential of 76 
nitroimidazoles, especially as novel antitubercular agents (11). Indeed, successful drug 77 
development efforts have resulted in the regulatory approval of delamanid (OPC-67683) for the 78 
treatment of multi-drug resistant tuberculosis (TB) by the European Medicines Agency (EMA) 79 
(12), while another bicyclic nitroimidazole compound, pretomanid (PA-824), is currently under 80 
investigation in Phase III clinical trials (13). In 2010, DNDi was granted access to a selected 81 
library of nitroimidazoles owned by the TB Alliance to speed up the development of novel 82 
therapies for neglected tropical diseases, including leishmaniasis. The antileishmanial activity of 83 
the nitroimidazooxazine DNDI-0690 (Figure 1) was first discovered in 2015; it is a structural 84 
analogue of DNDI-VL-2098 (14), a promising oral drug candidate for VL (15, 16) that was 85 
discontinued from further development due to toxicity issues identified during nonclinical CTA-86 
enabling studies (6). Given its superior safety profile, potent in vitro activity (EC50 = 0.17 μM) 87 
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5 
and excellent in vivo efficacy (> 99 % at 12.5 mg/kg p.o. twice a day in hamster models of VL) 88 
(17, 18), the decision was made in 2018 to progress DNDI-0690 into in Phase 1 clinical trials for 89 
VL. Furthermore, DNDI-0690 demonstrated excellent in vitro activity against three Old and 90 
three New World cutaneous Leishmania strains (EC50 < 5 μM). In a mouse model of L. major CL, 91 
oral DNDI-0690 exerted a linear dose-response effect (ED50 = 5 mg/kg, ED90 = 21 mg/kg, 92 
maximal efficacy > 95 % for 50 mg/kg), while topical solutions applied directly to the skin lesion 93 
were < 50 % active (19). 94 
With the clinical evaluation of DNDI-0690 for VL underway, important questions about the 95 
suitability, including appropriate PK and PD, of this nitroimidazole compound in the treatment 96 
of CL remain. The PK and PD properties required of drug to cure the two forms of leishmaniasis 97 
are not the same, due to (i) the different sites of infection that is the target for drug delivery 98 
(liver, spleen and bone-marrow versus dermal skin layers), (ii) possible differences in drug 99 
susceptibility between the causative parasites (L. donovani and L. infantum versus L. major, L. 100 
mexicana and other dermatropic Leishmania species) (20) and (iii) the potential impact of 101 
pathology on drug distribution. The aim of this study was to evaluate the PK and PD parameters 102 
of DNDI-0690 as part of efforts to develop much-needed new oral or topical drugs to treat CL. 103 
We therefore, determined the following properties of DNDI-0690: (i) in vitro drug disposition in 104 
skin upon topical dosing (Franz diffusion cells), (ii) in vitro protein-binding (BCA protein assay) 105 
and protein-binding corrected 50 % active drug concentrations against different CL-causing 106 
Leishmania species (fEC50), (iii) in vivo protein-free (e.g. pharmacologically active) drug exposure 107 
at the dermal site of infection (microdialysis) and (iv) in vivo time-kill kinetics of L. major and L. 108 
mexicana (bioluminescent parasite imaging).  109 
  110 
 o
n
 July 10, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
6 
Results  111 
In vitro topical drug penetration    112 
First, we evaluated topical drug penetration of DNDI-0690 into mouse skin in vitro using Franz 113 
diffusion cell permeation assays to investigate why the topical application of DNDI-0690 led to 114 
limited anti-leishmanial activity in murine models of CL (19). Table 1 shows skin distribution of 115 
topical DNDI-0690 into healthy and diseased but visibly intact skin (average nodule diameter 116 
4.10 ± 0.72 mm) harvested from L. major–infected BALB/c mice. Six hours after application of a 117 
solution of DNDI-0690 saturated in ethanol:propylene glycol (EtOH:PG) (0.063 % W/V), around 118 
99.5 % of the drug remained on the skin surface. Only a limited amount of drug (0.07-0.34 %) 119 
penetrated into the deeper layers of the (epi)dermis and 0.15-0.03 % passed through the skin, 120 
indicating poor dermal retention. There was no significant difference in drug quantity found in 121 
the different layers of the skin between L. major-infected and uninfected skin (p > 0.05).  122 
 123 
In vitro anti-leishmanial drug activity corrected for protein binding 124 
Second, in vitro 50 % effective concentrations (EC50) against Leishmania corrected for protein-125 
binding (fEC50) were calculated. This was done to enable comparison between in vitro PD 126 
measures (EC50  value based on total drug concentrations in the drug assay medium) and in vivo 127 
PK parameters obtained by microdialysis (non-protein bound drug concentrations). Therefore, 128 
protein-binding in the in vitro assay medium (RPMI containing 10 % heat-inactivated foetal calf 129 
serum, HiFCS) was estimated using a rapid equilibrium method. Drug-protein binding in the 130 
medium was moderate: 45.8 % at 0.2 µM and 53.1 % at 1 µM DNDI-0690. The mean % binding 131 
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7 
for DNDI-0690 (49.6 %) was used to determine fEC50, based on previously obtained EC50 values 132 
(19) and described in Table 2. 133 
 134 
In vivo skin pharmacokinetics   135 
Third, we studied the in vivo skin PK of DNDI-0690 in the L. major-BALB/c mouse model using 136 
microdialysis. After administration of either a single oral (50 mg/kg) or topical (30 µl 0.064 % 137 
w/v) dose of DNDI-0690 to the infected mice, free drug concentrations in the infected dermis 138 
(target site), the uninfected dermis (off-target site) and plasma (systemic circulation) were 139 
determined (Figure 2). After oral dosing at 50 mg/kg, DNDI-0690 showed a gastrointestinal 140 
absorption delay of 2.5 hours before reaching an fCmax of 275.4 ± 37.9 nM in the blood. 141 
Systemic drug concentrations remained stable in the following 3.5 hours, indicating a plasma 142 
half-life (T1/2) > 4 hours. Distribution volume (Vd) and elimination rate constant (Ke) values 143 
could not be estimated because no significant clearance of DNDI-0690 from plasma occurred 144 
within 6 hours of oral drug administration (tlast). The concentration of unbound DNDI-0690 in 145 
plasma was similar to unbound drug concentrations in infected and uninfected skin tissue and 146 
followed a comparable trend. Drug penetration from blood into skin tissue was high (fAUC0-6h, 147 
tissue / fAUC0-6h blood > 80 %) and maximal after 6 hours of oral dosing. However, DNDI-0690 148 
concentrations and overall drug distribution to cutaneous tissues were increased in uninfected 149 
in comparison to infected skin (Cmax = 365.3 ± 47.1 nM versus 263.7 ± 28.0 nM; AUC0-6h, tissue / 150 
AUC0-6h blood = 136.7 % versus 82.1 %, respectively). In contrast, after topical application of 50 µl 151 
DNDI-0690 saturated solution to the lesion, no drug was detected in the infected dermis within 152 
the following 6 hours. All results shown are corrected for in vitro relative recovery (RR) of DNDI-153 
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8 
0690 from the microdialysis probe. The RR was 18.6 ± 2.3 % and independent of concentration 154 
under in vitro experimental conditions mimicking those in vivo.  155 
 156 
In vivo antileishmanial pharmacodynamics  157 
Fourth, the time-kill kinetics of DNDI-0690 were characterised in two BALB/c mouse models of 158 
CL using bioluminescent L. major and L. mexicana parasites. Topical activity of DNDI-0690 was 159 
not evaluated due to poor skin permeation and low efficacy when administered via this route. 160 
After oral dosing of DNDI-0690 (50 mg/kg once daily for ten days), rapid and complete 161 
clearance of L. major and L. mexicana from the infected mice was observed (Figures 3 and 4, 162 
respectively). A 10-, 100- and close to 1000-fold reduction in L. major parasite load (relative to 163 
organism burden in untreated mice at the same time-point) was observed by days 2, 6 and 10, 164 
respectively. The maximal killing of L. major (99.5 %) was achieved 24 hours after the 10th and 165 
final dose of DNDI-0690 (day 10). At this point, the efficacy of DNDI-0690 was comparable to 166 
that of the positive control drug intravenous liposomal amphotericin B (LAmB, 99.7%) in this 167 
model. An identical regimen of once daily 50 mg/kg DNDI-0690 resulted in a 100-fold reduction 168 
in L. mexicana parasite burden by day 2. After two oral doses, the bioluminescent signal in the 169 
DNDI-0690 treated group was indistinguishable from that of the mice infected with wild-type, 170 
not-bioluminescent parasites. The activity of DNDI-0690 against L. mexicana was maximal (99.4 171 
%) and higher than that of LAmB (89.0%) at the end of treatment (day 10). Quantitative PCR 172 
was used to confirm the > 99 % reductions in parasite load for L. major- and L. mexicana-173 
infected mice treated with oral DNDI-0690 compared to untreated controls (Figures 3 (C) and 4 174 
(C), respectively). 175 
 176 
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9 
Discussion  177 
We have demonstrated the potential of DNDI-0690 as a novel treatment for CL by the oral 178 
route and the limited potential for its topical application. After oral administration at 50 mg/kg, 179 
DNDI-0690 is rapidly absorbed into the bloodstream and completely distributed to the skin, 180 
reaching near-maximal drug exposure at the site of action within 3 hours. At the dermal 181 
infection site, fCmax was lower (0.26 ± 0.03 µM) than fEC50 values for all tested Leishmania 182 
species (0.4 - 12 µM), indicating multiple doses could be needed to allow drug distribution to 183 
infected tissues and achieve cure. In vivo time-kill studies confirmed this was the case; in order 184 
to obtain a 100-fold reduction in lesion parasite load, 2 doses of 50 mg/kg were needed to clear 185 
L. mexicana (fEC50 = 0.96 µM) versus 6 doses for L. major (fEC50 = 3.15 µM). In both these 186 
bioluminescent Leishmania parasite CL mouse models, oral DNDI-0690 was as efficacious as the 187 
intravenous anti-leishmanial drug LAmB at the end of the 10-day treatment (> 99%). In 188 
contrast, topical administration of DNDI-0690 as a single application to the skin lesion did not 189 
result in measurable drug levels in the infected dermis. This may explain the low efficacy (< 50 190 
% reduction of lesion size and parasite burden determined by qPCR) of treatment via this route 191 
seen in earlier studies (19). These poor in vivo drug penetration kinetics, determined by skin 192 
microdialysis, were successfully predicted by in vitro Franz diffusion cell assays, which revealed 193 
the inability of DNDI-0690 to permeate the epidermis (> 99 % drug was recovered from the skin 194 
surface). Such assays therefore save time and resources for the design and development of new 195 
topical formulations to treat simple CL (21).  196 
To the best of our knowledge, this is the first time that skin microdialysis has been used to 197 
evaluate PK in Leishmania-infected mouse skin. The main technical advantage of this method 198 
for in vivo CL drug research is that it continuously measures protein-free (and, thus, 199 
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10 
pharmacologically active) drug concentrations directly in the dermal interstitial fluid 200 
surrounding the parasitized macrophages (22). Voelkner and colleagues employed a similar 201 
approach to evaluating the proposed anti-leishmanial drug pyrazinamide, although this 202 
experiment was performed in healthy rats (23).  203 
Interestingly, we observed differences in the PK of oral DNDI-0690 in Leishmania-infected and 204 
uninfected skin. Inflammation at the infection site in CL affects local drug distribution after 205 
intravenous administration of different formulations of amphotericin B (24, 25), as well as of 206 
topical drugs (26). Unbound DNDI-0690 concentrations in the dermal interstitial fluid could be 207 
lower in diseased than healthy skin, because while higher absolute amounts of drug may reach 208 
the skin tissue from the bloodstream (increased vascular permeability, vasodilation) (25), more 209 
drug could be bound to inflammatory proteins or engulfed by macrophages in the dermis. As 210 
neither protein-bound nor intracellular drug fractions are measured by microdialysis (27), this 211 
could explain the ultimately lower extracellular exposure of DNDI-0690 at the site of infection 212 
compared to uninfected counterparts. This finding illustrates the impact of the CL pathology on 213 
local drug distribution in the skin. Differences between amphotericin B and DNDI-0690 PK 214 
results could be related to the different sampling methodologies (skin necropsies and 215 
microdialysis, respectively).  216 
A limitation of this work is the single, high dose of oral DNDI-0690 (50 mg/kg) that was used 217 
during the PK and PD experiments. Further dose fractionation studies are required to identify 218 
the PK/PD driver of efficacy in CL (28). Combined with extended PK studies in mice and man 219 
(different dose levels and, time points > 6 hours), available data on the susceptibility of six 220 
parasite species and strains to DNDI-0690 can be used to set a robust PK/PD target estimate to 221 
inform the design of optimal clinical dosing regimens.  222 
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11 
In conclusion, the rapid oral absorption and potent activity of DNDI-0690 in skin lesions caused 223 
by L. major and L. mexicana support further development of this preclinical drug candidate as a 224 
new oral treatment for CL.  225 
 226 
  227 
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12 
Materials and methods  228 
Drugs and reagents. Oral DNDI-0690 was formulated in polyethylene glycol 400 (PEG400). The 229 
suspension was prepared in glass vials containing glass beads and sonicated (CamLab, 230 
Cambridge, UK) for 15 minutes before use. The dose levels and dosing frequency chosen were 231 
based on efficacy observed against VL (18) and CL (20). Topical DNDI-0690 was formulated as a 232 
saturated solution in propylene glycol-ethanol (PG-EOH, 1:1) to maximize permeation through 233 
the skin. The preparation was as follows. Excess of drug compound was added to a glass vial 234 
together with 1mL of PG-EtOH (1:1) and a magnetic stirrer. The vial was covered with 235 
aluminium foil and left at 34°C for 24 hours. An aliquot of this suspension was transferred to a 236 
vial and centrifuged for 15 min at 18,407 x g and 34°C after which the supernatant was 237 
transferred to a clean vial and stored at 4°C until drug administration. LC-MS/MS analysis 238 
confirmed the concentration of DNDI-0690 in this topical vehicle to be 0.063 % (W/V). Ringers 239 
solution was prepared at full strength (Sigma Aldrich) dissolved in 500 ml purified water) and 240 
autoclaved before use. 241 
Parasite maintenance, animals and ethical statement. The bioluminescent strains Ppy RE9H+L. 242 
major Friedlin (MHOM/IL/81/Friedlin) and Ppy RE9H+L. mexicana M379 (MNYC/BZ/62/M379) 243 
were kindly provided by Elmarie Myburgh and Jeremy Mottram (University of York, UK). L. 244 
major JISH WT (MHOM/SA/85/JISH118), Ppy RE9H+L. major Friedlin and, Ppy RE9H+L. mexicana 245 
M379 were maintained in Schneider’s medium supplemented with 10% heat-inactivated foetal 246 
calf serum (HiFCS) and passaged weekly (1:10). Female BALB/c mice (age 6-8 weeks) were 247 
purchased from Charles River (Margate, UK) and left to acclimatise for 5 days upon arrival. One 248 
day prior to infection, the rump above the tail was shaven using electric clippers. Twenty-four 249 
hours later, low-passage late-stationary phase promastigote cultures were centrifuged at 900 x 250 
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13 
g for 10 min at 4°C, counted using an improved Neubauer haemocytometer and re-suspended 251 
to 2 x 108 promastigotes per ml. Mice were subcutaneously injected in the rump with 200 µl of 252 
the suspension and randomly grouped (n=3-5). The mice were housed in a controlled 253 
environment of 55% relative humidity and 26°C and provided with tap water and a standard 254 
laboratory diet. All in vivo experiments were carried out under license (X20014A54) at the 255 
London School of Hygiene and Tropical Medicine (LSHTM) after discussion with the Named 256 
Veterinarian Surgeon and according to UK Home Office regulations. 257 
Bioanalysis of DNDI-0690 (LC-MS/MS). All samples were analyzed using a Shimadzu Nexera X2 258 
UHPLC/Shimadzu LCMS 860 at Pharmidex Pharmaceutical Services Ltd (Hatfield, UK). A mobile 259 
phase (0.4 ml/min) of water-0.1%formic (channel A) and acetonitrile-0.1%formic acid (channel 260 
B) was used to elute the sample compound from a Kinetex 5-µm XB-C18 column (2.1 mm by 50 261 
mm at 50 °C; Phenomenex, UK). The mobile phase composition was initially 2% B, programmed 262 
to increase linearly to 95% B at 1.1 minutes after injection. After 0.7 minutes at 95 % B, the 263 
composition was returned to its initial 2% B at 1.8 minutes post-injection. DNDI-0690 was 264 
detected by monitoring the transition of the parent molecule (mass-to-charge ratio (m/z) 370) 265 
to the fragment resulting from electrospray ionization (m/z 198.2). Analyte concentrations 266 
were quantified against calibration standards prepared in matched control matrices, with 267 
aliquots of samples, blanks and standards being injected at 5 µl. Lower limit of quantifications 268 
ranged between 0.5ng/ml and 50ng/ml for the microdialysis and skin extraction samples, 269 
respectively (Supplemental material 1). 270 
In vitro drug binding. The in vitro binding of the drug compounds to skin components was 271 
measured using the Rapid Equilibrium Dialysis single-use Device (Pierce Red Device, 272 
ThermoScientific). A 20 mM solution of DNDI-0690 in DMSO was used to spike RPMI-1640 273 
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14 
medium supplemented with 10% HiFCS to a final concentration of 0.2 and 1 µM of DNDI-0690. 274 
Three hundred µL of the DNDI-0690 containing medium was transferred to the sample chamber 275 
and 550 µL of Ringers solution was added to the buffer chamber. This was done in triplicate for 276 
each DNDI-0690 concentration. The RED device was left to incubate in an orbital shaking 277 
incubator (200 rpm) at 34 °C for 4 hours. From each chamber, 50 µl aliquots were collected and 278 
matrix matched after which 2 volumes of ice cold ACN were added. After another 20 minutes, 279 
100 µL of each mixture was centrifuged for 15 minutes at 21,130 x g at 4°C. The supernatants 280 
were assayed for the parent drug by LC-MS/MS.  281 
Franz diffusion cell permeation and drug disposition. Female BALB/c mice (n=5) were injected 282 
subcutaneously with 4 x 107 L. major promastigotes above the tail. In time, a nodule developed 283 
at the injection site and when this reached 4 to 5mm the mice were sacrificed using CO2. Two 284 
circular skin discs (approximately 15 mm diameter) were obtained per donor mouse; one 285 
containing the leishmaniasis nodule (average ± sd) that was collected from the lower dorsal 286 
area above the tail and another disc of unaffected skin that was collected from the area higher 287 
up the back of the mouse. Fat and muscle tissue were carefully removed using forceps and the 288 
skin was gently stretched on Whatman filter paper. The skin was placed between the greased 289 
donor and receptor compartment of the Franz cell with a narrow diameter (5 mm). PBS was 290 
sonicated for 30 minutes and added to the receptor compartment together with a small 291 
magnetic stirrer. The Franz cells were placed on the magnetic stirrer plate (800 rpm) in a warm 292 
water bath until the skin temperature reached a steady 34°C. Next, the DNDI-0690 saturated 293 
solution (30µL of 0.064% (W/V) DNDI-0690 in PG: EtOH (1:1)) was applied to the skin and 100 µl 294 
of receptor solution was replaced with fresh PBS at regular time intervals over a period of 6 295 
hours and analysed by LC-MS/MS. At the end of the experiment, the cells were dismantled and 296 
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the donor chambers of the Franz cells were washed with 1 ml of acetonitrile: water solution 297 
(ACN: H2O (1:1)). Any drug remaining on the skin surface was removed using a clean dry cotton 298 
swab. The amount of drug in the washing liquid and the cotton swab was quantified using LC-299 
MS/MS. To extract DNDI-0690 from the skin, the skin disc was homogenised in 1 ml of PBS as 300 
described above. 100 µL of this homogenate was protein precipitated using 300 µL of ice-cold 301 
ACN (100 %) and, centrifuged at 13,000 rpm for 30 mins at 4°C. An aliquot of the supernatant 302 
was diluted with an equal volume of water and stored for analysis by LC-MS/MS at -80°C. 303 
Together the amount of drug recovered from the skin surface, extracted from the skin and 304 
permeated through the skin was satisfactory when ranging from 70-110%.  305 
Microdialysis system. MAB 1.2.4. Cu probes (Microbiotech, Sweden) with a 6kDa cut-off 306 
cuprophane membrane were used in vitro for recovery determination and in vivo for 307 
microdialysis. The cuprophane membrane of this concentric probe is 2 mm long and has an 308 
outer membrane diameter of 0.2 mm; inlet and outlet tubing consisted of fluorinated ethylene 309 
propylene (FEP) with lengths of 25 and 50 cm, respectively. A syringe pump (11 plus model 70-310 
2208, Harvard Apparatus, USA) was used to circulate the perfusate (Ringers solution) at a flow 311 
rate of 2 µl/minute. Dialysates were automatically collected in glass vials (Thermo Fisher, UK) 312 
using a refrigerated fraction collector (MAB 85, Microbiotech, Sweden) at 30 minutes set 313 
intervals. For accurate measurement of in vivo free drug concentrations at the dermal site of 314 
action, raw microdialysis values were corrected for the loss of compound due to incomplete 315 
equilibration between the sampling medium and the perfusate and/or sticking of the drug to 316 
the outlet tubing of the microdialysis probe, expressed as the relative recovery value (22). 317 
Recovery rates for the microdialysis equipment were determined in vitro as follows: three 318 
probes were placed in a reservoir containing DNDI-0690 at concentrations of 30 or 120 ng/ml in 319 
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16 
Ringers solution at 34 °C (mimicking in vivo skin temperature). The probes were perfused with 320 
Ringers solution at a flow rate of 2 µl/minute and microdialysates were collected every 15 321 
minutes. All samples were analysed using LC-MS/MS after the addition of 10 µl acetonitrile 322 
(ACN) (1:3 ratio for 30 µl sample volume). Relative recovery (RR) was calculated as the ratio of 323 
the analyte concentrations in the microdialysate over the analyte concentration in the reservoir 324 
medium.    325 
In vivo microdialysis. L. major JISH-infected BALB/c mice (n=6) with shaven rump and back 326 
were anaesthetised with 1.6 g/kg urethane (IP). Two hundred µl Ringers physiological solution 327 
was immediately administered via the neck scruff (SC) to prevent dehydration during long-term 328 
(6-8 hour) anaesthesia. Mice were placed on a temperature-controlled heating pad (Peco 329 
Services Ltd, Cumbria, UK) to maintain body temperature at 32 ± 2 °C. MAB 1.2.4. probes were 330 
inserted in the following positions using a 22 G needle: the dermal skin layer of the CL lesion on 331 
the rump, the dermal skin layer of the healthy control skin higher up on the back and the tail 332 
vein (Figure 5). To equilibrate the system and allow the skin and tail vein to recover from the 333 
probe insertion trauma, a stabilisation period of 30 minutes (23) of perfusion with Ringers 334 
solution at a flow rate of 2 µl/min was included before collecting samples. At the start of the 335 
pharmacokinetic experiment, half of the mice (n=3) received 50 mg/kg DNDI-0690 via oral 336 
gavage. This dosage has been shown to significantly reduce the lesion size (20). The other three 337 
mice received 30 µl of a 0.064 % (W/V) saturated solution (maximal driving force of 1) applied 338 
topically to the skin lesion on the rump of the mice. Samples were collected every 30 minutes at 339 
a flow rate of 2 µl/min. After the addition of 20 µl acetonitrile (1:3 ratio for 60 µl sample 340 
volume) samples were stored at – 80 °C before analysis by LC-MS/MS. Temperature, breathing 341 
 o
n
 July 10, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
17 
pattern and behaviour of the anaesthetized mice were monitored constantly. At the end of the 342 
experiment, mice were culled by pentobarbital overdose.  343 
Single-dose PK parameters were calculated by plotting the DNDI-0690 concentrations measured 344 
in the dialysate of the probe placed in the blood vene, the infected and uninfected skin over 345 
time. The fCmax for each matrix (blood, infected and uninfected skin) is the highest drug 346 
concentration reached in each respective matrix throughout the experiment. fAUC0–6h values 347 
for the blood and infected and uninfected skin were calculated using GraphPad Prism, version 348 
7.02. Data are presented as mean and standard error of the mean (SEM). 349 
Rate-of-kill by in vivo bioluminescence imaging. Thirty-six female BALB/c mice were purchased 350 
and prepared for infection as described above. Fifteen mice were injected with 4 x 107 351 
stationary phase luciferase-expressing L. major Friedlin (Ppy RE9H+L. major Friedlin) 352 
promastigotes, fifteen were injected with luciferase-expressing L. mexicana M379 (Ppy RE9H+L. 353 
mexicana M379) (23) and six were infected with L. major JISH WT parasites that do not express 354 
luciferase. Upon appearance, nodule diameters were measured in two directions daily. When 355 
the size progressed to 6.73 ± 1 mm for the L. major Friedlin-infected mice, they were allocated 356 
into groups of five with similar average nodule diameters (p>0.5, One-Way ANOVA) and 357 
treatment was initiated. For the Ppy RE9H+L. mexicana M379, no lesions developed and 358 
treatment was started when the bioluminescence signal reached 5.02 (± 3.27) x 106 359 
radiance/second. Each experiment included an untreated control (n=5), baseline control (L. 360 
major JISH WT, n=3), positive control (AmBisome®, iv, 25mg/kg, QAD, n=5) and a DNDI-0690 361 
group (50 mg/kg, po, QD, n=5). A topical administration group was not included due to 362 
previously observed inactivity. The bioluminescent signal was measured prior to administration 363 
of the first drug dose and every other day thereafter until the baseline signal was reached. Ten 364 
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minutes before acquiring the bioluminescent signal, mice were injected with 150 mg/kg 365 
luciferin (d-luciferin potassium salt, (Bertin Bioreagent), then anesthetized using 3 % (vol/vol) 366 
gaseous isoflurane and placed in an IVIS Lumina II system (Perkin Elmer). Images were acquired 367 
10 minutes after luciferin injection using LivingImage v4.3. A circular region of interest (ROI) 368 
encompassing the nodular area on the rump was drawn to quantify bioluminescence expressed 369 
as radiance (photons/second/cm2/sr). Background radiance was measured from mice infected 370 
with L. major JISH WT. Parasite burden in the skin was confirmed by DNA-based qPCR, as 371 
described earlier (24). 372 
Statistical analysis. For the in vitro topical drug penetration experiment, differences between 373 
DNDI-0690 concentrations in healthy and infected skin were compared using student t-test 374 
(Prism v 7.02, Graphpad). To compare differences in qPCR parasite load in skin lesions, 1-way 375 
analysis of variance (ANOVA) followed by Dunnett’s multiple-comparison test was performed. A 376 
P value of <0.05 was considered statistically significant.  377 
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Tables 479 
Table 1. Disposition of topically applied DNDI-0690 in the skin of L. major-infected BALB/c mice 480 
using Franz diffusion cells. The total amount of DNDI-0690 per FDC recovered at the end of the 481 
experiment was considered 100%. The amounts of DNDI-0690 recovered from the different 482 
sites were expressed as a fraction of this amount. The table shows the average % (± SD), 483 
(infected n=5, uninfected n=3).  484 
DNDI-0690 localisation  Uninfected skin  Infected skin P-value (t-test) 
On skin  
(DNDI-0690 in wash and cotton swab) 
99.63 (± 0.39) 99.77 (± 0.19) 0.49 
In skin  
(DNDI-0690 extracted from skin homogenate) 
0.34 (± 0.39) 0.07 (± 0.07) 0.16 
Through skin  
(DNDI-0690 in receptor fluid) 
0.03 (± 0.05) 0.15 (± 0.15) 0.227 
 485 
Table 2. Protein binding-corrected 50 % effective concentrations (fEC50) of DNDI-0690 against 486 
several  cutaneous Leishmania species (n is the number of experiment repeats). 487 
CL- causing Leishmania species n EC50 (µM) fEC50 (µM) 
L. major (MHOM/SA/85/JISH118) 1 
2 
4.56 
7.94 
2.28 
3.97 
L. tropica (MHOM/AF/2015/HTD7) 1 
2 
1.41 
2.38 
0.71 
1.19 
L. aethiopica (MHOM/ET/84/KH) 1 
2 
24.61 
< 0.33 
12.31 
< 0.165 
L. mexicana (MNYC/BZ/62/M379)  1 
2 
1.91 
<1.11 
0.96 
<0.56 
L. panamensis (MHOM/PA/67/BOYNTON) 1 0.77 0.39 
L. amazonensis DsRed2  
 
1 < 1.11 < 0.56 
 488 
 489 
  490 
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Figure legends 491 
Figure 1. The chemical structure of DNDI-0690. 492 
 493 
Figure 2. Skin PK of DNDI-0690 in the L. major-BALB/c mouse model of CL after oral (left - each 494 
mouse had 3 probes inserted: tail vein, healthy and lesion skin) and topical (right - each mouse 495 
had 1 probe inserted: lesion skin) drug administration. Data represent protein-free drug 496 
concentrations (average concentration (nM) ± SD (n=3)), corrected for probe recovery.  497 
 498 
Figure 3. Anti-leishmanial efficacy of oral DNDI-0690 (50 mg/kg, once daily for 10 days) in an 499 
‘Old World’ CL model (L. major Friedlin REH infection of BALB/c mouse). (A) shows the parasite 500 
load, as indicated by in vivo imaging of bioluminescent parasites in the infected rump skin over 501 
time. (B) shows the bioluminescence signal on day 11 (24 hours after the last drug dose 502 
administration) and (C) confirms the parasite load on day 11 using qPCR. QD = once daily, QAD 503 
= once every 2 days, po=oral drug administration, iv= intravenous drug administration.  * = p > 504 
0.05.  505 
 506 
Figure 4. Anti-leishmanial efficacy of oral DNDI-0690 (50 mg/kg, once daily for 10 days) in a 507 
‘New World’ CL model (L. mexicana M379 REH infection of BALB/c mouse). (A) shows the 508 
parasite load, as indicated by in vivo imaging of bioluminescent parasites in the infected rump 509 
skin over time. (B) shows the bioluminescence signal on day 11 (24 hours after the last drug 510 
dose administration) and (C) confirms the parasite load on day 11 using qPCR. QD = once daily, 511 
QAD = once every 2 days, po=oral drug administration, iv= intravenous drug administration.  * = 512 
p < 0.05. ** = p < 0.01.  513 
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 514 
Figure 5. Schematic of the experimental set-up of the in vivo microdialysis in mice with CL. 515 
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